Articles
11 June 2009
Vol. 3 No. 1: 2006...2009: Now we know T-cell lymphomas better, Bologna, Italy, 16-18 March 2009
https://doi.org/10.4081/hmr.v3i1.551

High-dose therapy and autotransplantation in peripheral T-cell lymphoma and cutaneous T-cell lymphoma

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
176
Views
337
Downloads

Authors

P Reimer
support@pagepress.org
Peripheral T/NK-cell lymphomas (PTCL) comprise a rare and heterogeneous group of malignancies accounting for approximately 10-15% of all non- Hodgkin’s lymphomas (NHL) in Western countries. PTCL in general are characterized by an aggressive course and most studies revealed the T-cell phenotype as a negative prognostic marker.1-4 The international prognostic index (IPI) and T-cell specific prognostic index (PIT) have shown prognostic value in PTCL determining the outcome of patients with nodal peripheral T-cell lymphomas.5-8

Altmetrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite



High-dose therapy and autotransplantation in peripheral T-cell lymphoma and cutaneous T-cell lymphoma. (2009). Hematology Meeting Reports (formerly Haematologica Reports), 3(1). https://doi.org/10.4081/hmr.v3i1.551